BIOLASE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.182 USD | +7.76% |
|
+3.51% | -83.69% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -83.69% | 5.62M | - | ||
| +11.11% | 226B | B | ||
| +8.81% | 188B | B- | ||
| +13.21% | 137B | B- | ||
| +25.93% | 108B | A- | ||
| +0.34% | 63.19B | A- | ||
| +11.28% | 52.26B | B+ | ||
| +5.62% | 51B | B+ | ||
| +6.00% | 43.89B | A | ||
| +4.68% | 38.07B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOL Stock
- Ratings BIOLASE, Inc.
